COMPANY

Siolta Therapeutics, Inc.

HQ: San Carlos, CA source · sioltatherapeutics.com ↗ · West Coast

Keywords: microbiome Atopic Dermatitis Type 1 Hypersensitivity Atopic Immunoglobulin E-Mediated Allergic Disorder necrotizing enterocolitis STMC-103H

Location: San Carlos, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $935K (SBIR Phase II 5R44AI195248-02, continuation, notice Jul 14, 2026). NIH RePORTER 5R44AI195248-02 (Jul 14, 2026)
Evidence (1 event)
- Jul 14, 2026 · NIH RePORTER 5R44AI195248-02
  Organization: SIOLTA THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 5R44AI195248-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 935435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 14, 2026 Grant Government grant — SBIR: $935,435 (annual award, as published), announced Jul 14, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Nov 13, 2025 Grant Government grant: $1.8M (total, as published), announced Nov 13, 2025. Source: company's own press page. source ↗
Nov 13, 2025 Grant Government grant: $3M (total, as published), announced Nov 13, 2025. Source: company's own press page. source ↗
Aug 5, 2025 Grant Government grant — SBIR: $529,498 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Mar 20, 2025 Partnership Partnership / licensing announced Mar 20, 2025. Source: company's own press page. source ↗
Sep 1, 2021 Trial start Phase 1/Phase 2: Allergic Disease Onset Prevention Study source ↗
Oct 10, 2018 Trial start 1: A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy source ↗

Last 2 years.

Mar 20, 2025 Partnership / licensing announced Mar 20, 2025. Source: company's own press page. source ↗
Jul 14, 2026 Government grant — SBIR: $935,435 (annual award, as published), announced Jul 14, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Nov 13, 2025 Government grant: $1.8M (total, as published), announced Nov 13, 2025. Source: company's own press page. source ↗
Nov 13, 2025 Government grant: $3M (total, as published), announced Nov 13, 2025. Source: company's own press page. source ↗
Aug 5, 2025 Government grant — SBIR: $529,498 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05003804	Allergic Disease Onset Prevention Study	Phase 1/Phase 2	Completed	Sep 1, 2021	Nov 26, 2024 (actual)
NCT03819881	A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy	1	Unknown status (ClinicalTrials.gov)	Oct 10, 2018	2019-11 (estimated)

Annual award amounts. Total $3.2M.

Jan 11, 2024 NIH award 5R44AI170366-03 FY2024: $948,833 awarded for that fiscal year; activity R44 (SBIR); PI VALLADARES, RICARDO; recipient as written: SIOLTA THERAPEUTICS, INC., SAN CARLOS, CA. Anaerobic Manufacturing and Molec source ↗
Aug 14, 2023 NIH award 1R43AI179503-01 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI VALLADARES, RICARDO; recipient as written: SIOLTA THERAPEUTICS, INC., SAN CARLOS, CA. A Synergistic Multistrain Live Bi source ↗
Jan 19, 2023 NIH award 5R44AI170366-02 FY2023: $993,238 awarded for that fiscal year; activity R44 (SBIR); PI VALLADARES, RICARDO; recipient as written: SIOLTA THERAPEUTICS, INC., SAN CARLOS, CA. Anaerobic Manufacturing and Molec source ↗
Feb 3, 2022 NIH award 1R44AI170366-01 FY2022: $979,061 awarded for that fiscal year; activity R44 (SBIR); PI VALLADARES, RICARDO; recipient as written: SIOLTA THERAPEUTICS, INC., SAN CARLOS, CA. Anaerobic Manufacturing and Molec source ↗